VIMOVO

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG

Commercializzato da:

ASTRA ZENECA ISRAEL LTD

Codice ATC:

G02CC02

Forma farmaceutica:

TABLETS MODIFIED RELEASE

Via di somministrazione:

PER OS

Prodotto da:

ASTRA ZENECA AB., SWEDEN

Gruppo terapeutico:

NAPROXEN

Indicazioni terapeutiche:

Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Data dell'autorizzazione:

2011-12-01